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Abstract
Cardiogenic shock (CS) still carries an unacceptably high mortality (30–60%), despite 
several therapeutic approaches; the SHOCK II trial questioned the benefit of intra-aortic 
balloon pump (IABP), while IMPRESS and CULPRIT-SHOCK trials confirmed hetero-
geneity in disease spectrum and patient selection for acute myocardial infarction-related 
CS requiring acute mechanical circulatory support (AMCS). The heterogeneity of devices 
employed as AMCS, including temporary micro-axial flow pumps (Impella), percutane-
ous bypass (TandemHeart), and extracorporeal life support (VA-ECMO), contributed to 
the actual dramatic scenario, where CS is defined clinically rather than hemodynami-
cally. To date, the role of VA-ECMO is emerging as rapid strategy to mitigate mortality 
rates of severe refractory states, despite the lack of data regarding the best practices of 
management and flows control. VA-ECMO’s flow represents the “dose” of treatment and 
higher flows are less tolerated percutaneously requiring, to prevent deleterious pulmonary 
edema and ventricular distention, additional approaches such as pulmonary, left atrial, or 
left ventricular unloading. Any efforts have to be directed to (1) determine adequate man-
agement of patients on VA-ECMO, (2) define the safer duration of VA-ECMO support, and 
(3) establish algorithms and techniques to predict and obtain stable weaning from ECMO 
or ensure fast transition to durable VAD and/or heart transplant.
Keywords: ECMO, myocardial recovery, cardiogenic shock, ventricular unloading, 
VA-ECMO, Impella, ECLS, ECPELLA, ECMO dose retrieval
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1. Introduction
Cardiogenic shock (CS) continues to exhibit a high mortality rate (30–60%), despite several 
therapeutic approaches; recent data derived from the SHOCK II trial [1] questioned the benefit 
of intra-aortic balloon pump (IABP) in the treatment of the CS. Subsequently, IMPRESS [2] and 
CULPRIT-SHOCK [3] confirmed heterogeneity in disease spectrum (using a non-hemodynamic 
clinical definition for CS) and patient selection for AMI-related cardiogenic shock requiring 
acute mechanical circulatory support (AMCS) with alternative strategies to counterpulsation 
such as temporary micro-axial flow pumps (Impella), percutaneous left atrium-aortic bypass 
(TandemHeart) and venoarterial extracorporeal membrane support (VA-ECMO) [4]. In this dra-
matic clinical scenario, VA-ECMO is emerging as an alternative strategy to mitigate such elevated 
mortality. Although a beneficial effect on peripheral perfusion/circulation has been demonstrated 
with VA-ECMO implantation in patients affected by CS, there is a potential for increasing load-
ing conditions into the left ventricle potentially compromising transition to myocardial recovery. 
Contemporary VA-ECMO systems are now widely used with a broad spectrum of configura-
tions. Due to case mix and implantation timing differences (from report to report and depending 
on the institutions), outcomes have wide variability and are limited by its retrospective nature 
and lack of granular profiling prior and after support. The timing of the implantation potentially 
accounts for further differences in outcomes between different institutions. Central cannula-
tion, when feasible, warrants the best peripheral flows, the best cardiac perfusion, and unloads 
adequately both ventricles but is still complicated by a high incidence of bleeding and need of 
multiple re-sternotomy. Moreover, central VA-ECMO is not always bedside available. Despite 
the growing experience in the use of VA-ECMO, the target flow has still not been identified, and 
in literature, there is a lack of data regarding best practices with management. Indeed, VA-ECMO 
flow represents the “dose” of the treatment: the lower dose corresponding to lower flow may be 
readily achieved through percutaneous cannulation, while the higher the dose or higher flow can 
be obtained through larger cannulas (Figure 1) and may require modifying VA-ECMO configu-
ration during support aiming to prevent the common complications due to overflow. However, 
a higher flow warrants optimal peripheral organ perfusion, lower venous pressure, and higher 
mean pressure. The decongestion of the venous side appears a critical factor in recovery end-
organ function and is pivotal both for renal and liver function recovery. The building of the circuit 
should always aim at the lowest venous pressure to restore a normal perfusion pressure despite 
low continuous flow pressure. On the other hand, high flow not only induces highly turbulent 
flows, increasing shear stress, and damaging platelets but also increase the quota of shunt and 
the left ventricular afterload. The latter mechanism may explain the increased risk of pulmonary 
edema and moreover the reduced hazard of myocardial recovery [5].
Preventing pulmonary edema is one of the principal targets to reduce the biologic impact of 
VA-ECMO and possibly to maintain the patients extubated and even ambulatory. A large 
number of possible approaches have been described to aim through a small-incision pul-
monary, left atrial, or left ventricular unloading, thus preventing pulmonary edema. The 
implantation of a double ECLS (extracorporeal life support) circuit (surgical with CentriMag 
or percutaneous with TandemHeart) thus aiming to reduce all the possible complications due 
to the need of an oxygenator [6–8] represents one of the possible solutions.
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Today, the first indication of treatment is myocardial recovery as clearly shown both from 
data coming from leading centers in the VA-ECMO implantation and ELSO registries [9, 10]. 
This target is more frequently achieved in myocarditis or potentially reversible diseases [11] 
and stresses the importance of etiological diagnosis at the moment of implantation to define 
the strategy of implantation. To warrant optimal outcomes, many efforts have to be directed 
to:
1. Determine adequate management of patients on VA-ECMO.
2. Minimize the time the patient is on VA-ECMO.
3. Establish algorithms and techniques to predict and obtain stable weaning from VA-ECMO.
When pathology is reversible, probably, the quality of myocardial unloading can potentially 
make an essential difference in the platform for transition (recovery vs. VAD and/or heart 
transplant). Recent data support the need to reason about a transition to a midterm platform 
as soon as a stable organ perfusion and function have been warranted, possibly between day 7 
[12] and before day 14 [13]. Data emerging on the beneficial effect of early myocardial unload-
ing on the acutely failing hearts with temporary micro-axial flow pumps continue to arise 
[14–16]; however, there is no clear consensus or longitudinal hemodynamic data to support 
a specific combination or transition strategy for severe refractory, hemometabolic, and/or 
biventricular cardiogenic shock, and although it appears that the most commonly described 
combination is VA-ECMO with LV unloading via an Impella device, the emerging alternative 
Figure 1. ECMO configuration tailored on needed flow. Representation of the existing relation from type of cannula, site 
and technique of insertion and flow rates. The figure defines that according to the needed flow the operator may utilize 
different approaches starting from lower flows provided with a femoral percutaneous small nonocclusive cannula (blue 
dot) reaching the higher flows with a large cannula in central ECMO or BiVAD.
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of high-profile biventricular support with combination of Impella 5.0 and RP or percutaneous 
biatrial VA-ECMO is also possible.
This chapter aims to evaluate best practices and strategies that can be implemented to prevent 
and reduce ventricular distention and to increase the likelihood of recovery and survival dur-
ing and after VA-ECMO support.
2. Incidence of complications and ECMO configuration
VA-ECMO currently represents the most effective minimally invasive circulatory support 
system. VA-ECMO has evolved and can now be placed quickly at the bedside, in the medical 
unit, or in the cardiac intensive care unit. It provides oxygenation, it is the best option in the 
setting of associated lung injury, it can be placed peripherally (without thoracotomy), and it 
is the only percutaneous option for biventricular support. It may provide sufficient support 
to enable adequate tissue perfusion even in cardiac arrest, and it is a suitable device for acute 
resuscitation of a patient in shock, even if mortality for cardiogenic shock did not significantly 
change and is still ranging between 50 and 70% [17].
Moreover, many publications have disclosed a dramatic burden of complications using per-
cutaneous VA-ECMO leading to higher costs and ethical discussions on the right clinical set-
tings for its clinical adoption [9, 18–20].
Looking critically at the landscape of effects and complications of different configurations 
of mechanical circulatory support and specifically of VA-ECMO emerges the importance to 
select the right device and the right VA-ECMO’s configuration to warrant the best outcome. 
The crucial factor in selecting the device and the VA-ECMO’s configuration is the amount of 
flow needed to restore organ function. Venous oxygen saturation has been indicated by many 
authors as a good goal to direct VA-ECMO perfusion [21].
Percutaneous VA-ECMO appears fitted to restore peripheral flows when the patient experi-
ences a moderate reduction of cardiac output. When the patient needs higher flows, the risk 
of pulmonary edema and left ventricular distention increases [22], and additional cares may 
be necessary to unload the left ventricle and eventually to restore pulmonary function after 
pulmonary edema [23–25].
Although a beneficial effect on peripheral perfusion/circulation has been demonstrated with 
VA-ECMO implantation in patients affected by cardiogenic shock, there is a potential for 
increasing loading conditions into the left ventricle potentially compromising transition to 
myocardial recovery. Contemporary VA-ECMO systems are increasingly being used with a 
wide spectrum of configurations.
3. Destination of VA-ECMO
Contemporary registries and center reports support the ultimate finality of therapy for acute 
decompensated heart failure being myocardial recovery [26]. When pathology is reversible, 
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the time to recovery on the basis of the etiopathology of the disease plays a pivotal role 
together with the modality of support aiming to help myocardial healing [27].
Therefore, if during the acute phase of VA-ECMO implantation the “dose” is a critical fac-
tor to recovery the end-organ function, the complementary goal is to reduce the biologic 
impact of support and favor myocardial healing. Many data are emerging in support of a 
role of myocardial unloading to reach this aim [28]. Data coming out from experimental 
data on animal and computer simulations seem to support the hypothesis that ventricular 
unloading is more effective than atrial unloading. Data emerging on the beneficial effect of 
early myocardial unloading on the acutely failing hearts with temporary micro-axial flow 
pumps continue to arise; however, there is no clear consensus or data to support a specific 
combination or transition strategy for severe refractory, hemometabolic, and/or biventricular 
cardiogenic shock.
VA-ECMO has multiple effects on the left ventricular myocardium:
• The decrease of venous return and the volume work may reduce the wall tension of the 
heart and subsequently the LVEDV and LVEDP.
• The increase of arterial pressure (MAP) and reduction of venous pressure improve the 
pressure gradient and then the myocardial perfusion.
• The increase of blood pressure increases afterload and the pressure work of myocardium 
affecting the Frank-Starling law.
The overall effect of the decrease in volume work and the increase in pressure work depends 
on the “dose” of VA-ECMO as well as myocardial function and its response to these phenom-
ena. Peripheral ECMO with a high flow may further increase afterload due to the reversal of 
flow in the most of the aorta [29, 30].
The real question remains if myocardial unloading is always beneficial or potentially detri-
mental by increasing the complexity of management and when is indeed indicated the transi-
tion from ECMO support to ECMO + LV unloading.
Although it appears that the most commonly described combination is VA-ECMO with LV 
unloading via an Impella device, the emerging alternative of high-profile biventricular sup-
port with the combination of Impella 5.0 and RP or percutaneous biatrial ECMO is also pos-
sible valuable solutions [31].
Many contradictory data are emerging regarding the effect of VA-ECMO on LV contractile 
function. LV afterload before ECMO is related to systemic arterial pressure, and the Starling 
curve generated before initiation of ECMO flow predicts the filling pressure associated with 
any target SV at that systemic pressure. The addition of ECMO flow or alterations solely 
in SVR does not alter the relationship between filling pressure and native LV SV, and then 
the abrupt increase of afterload due to the ECMO flow may be useful to predict ventricular 
distension during ECMO support [32].
In the presence of severe LV dysfunction, the left ventricle is unable to eject a sufficient volume 
of blood against the increased afterload caused by the ECMO flow, resulting in impairment of 
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various parameters of LV performance [33–35] and, in extreme situations, the aortic valve can 
remain closed even during systole.
When VA-ECMO is established due to ongoing cardiogenic shock, it is possible to measure 
PCWP and LV SV directly. The additional systemic flow conferred by ECMO may be offset by 
volume reduction of venous return that may cause a reduction in PCWP. When VA-ECMO is 
established for cardiogenic shock due to right ventricle failure, PCWP is typically low, and the 
LV is relatively afterload insensitive.
The presence of a pulse pressure depends (without IABP) on the stroke volume of the left ven-
tricle. The absence of arterial pulsatility may prove an appropriate level of support (60–80% 
of the predicted cardiac output allowing for the remaining 20–40% to pass through the lungs 
and heart). However, on the other end, it indicates also the inability of the myocardium to 
overcome the superimposed afterload worsened by a decreased preload and volume work.
When mitral regurgitation is absent, and a significant amount of blood returns in the LV, blood 
may stagnate within the left ventricle and at the aortic root. The persistent closure of the aortic 
valve may increase the risk of thrombus formation and subsequent embolic. Besides, the reduc-
tion of the stroke volume and of the transmitral flow due to VA-ECMO, the increase of the 
PCWP, the persistent venous return from thebesian and bronchial veins lead to overdistension 
of the LV. The distention of the LV measured in terms of LVEDV leads to an LVEDP; impairing 
coronary perfusion pressure may further worsen the ischemic subendocardial injury to the 
myocardium. In some instance, left ventricular distension may cause tethering of a previously 
competent mitral valve causing functional mitral insufficiency due to annular dilation. In this 
scenario, a pulmonary artery catheter may demonstrate an increase in the telediastolic pulmo-
nary capillary occlusion pressure. The presence of severe mitral regurgitation may worsen left 
atrial hypertension congesting the pulmonary bed leading to pulmonary edema and even hem-
orrhage. Functional assessment of the heart in a partially bypassed state can be challenging, but 
transesophageal echocardiography may aid in confirming aortic valve opening as well as by 
providing an assessment of the variations of the left ventricular end-diastolic dimension after 
VA-ECMO institution. The serial evaluation of LVED and of the PCWP should be routinely 
used during VA-ECMO to give a prompt indication to LV unloading when the simple physio-
pathologic and/or eventual simulation models do not already suggest the need of an unload-
ing. Recently, the option to first unload and then evaluate the need of VA-ECMO has been 
prompted. The increase in systemic pressure, in this scenario, is slight, and a modest increase 
in PCWP would accompany the increase in LV afterload without a significant change in LV SV.
When VA-ECMO is established for cardiogenic shock due to acute LV failure, the magnitude 
in afterload change depends on the increase of systemic pressure. In this scenario, if PCWP is 
already high and without a substantial improvement in LV contractility, a dramatic rise in PCWP 
with LV distension is expected. LV and pulmonary venous distension lead shortly to a massive 
acute pulmonary edema and blood stasis in the left heart with a serious risk of thrombus forma-
tion. Prompt diagnosis and a high suspicion have to be kept in this situation as it is imperative 
to both unload the central circulation while maintaining a minimal LV SV. The effectiveness of 
oxygenation and drainage is a vital factor for the diagnosis as if the patient is well drained and 
perfused; the diagnosis of pulmonary edema may be masked by ECMO. VA-ECMO differs from 
the standard cardiopulmonary bypass circuit due to the absence of a venous reservoir halting 
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the possibility to control the amount of venous return to the left heart during VA-ECMO; the 
blood volume bypassing the venous cannula due to incomplete drainage or coursing through 
the bronchial circulation returns to the left heart; this represents the additional LV output to 
VA-ECMO flow in the systemic circulation. While this additional flow may be altered by changes 
in circulating blood volume (e.g., diuresis), the LV will require a preset inflow pressure warrant-
ing to deliver a target SV (to prevent blood stasis) depending on the Starling relations. The risk 
of ventricular distention after initiation of VA-ECMO is related to the preinitiation EF in a setting 
of high afterload sensitivity as contractile strength is reduced. Even a moderate reduction in pre-
ECMO EF (less than 50%) may predict high PCWP after VA-ECMO institution, due to the abrupt 
increase of systemic pressure and afterload when peripheral cannulation is accomplished.
Placed in the setting of hypotension and cardiogenic shock, the increase in MAP after initia-
tion of VA-ECMO is associated with a significant increase in PCWP and decrease in LV SV, 
counteracting the emptying of the ventricle and its work.
Careful management of patients on VA-ECMO should include monitoring of intravascular 
volume status, MAP, and PCWP.
Volume status should be managed in a way to warrant a minimally acceptable LV SV, while 
the MAP should be kept down acting on VA-ECMO flow rates and by pharmacologic manip-
ulation of SVR. VA-ECMO flows can be reduced in an attempt to reduce afterload. However, 
this maneuver may not be possible if it compromises oxygen delivery and end-organ perfu-
sion due to the inability of the heart to produce a compensatory increase in native cardiac 
output. The value of PCWP depends on LV contractility and MAP but not on the method by 
which MAP is controlled while maintaining a minimal LV SV.
LV overload and distension except for pulmonary edema may induce increased wall stress and 
myocardial oxygen consumption [36]. During acute decompensation of chronic heart failure 
leading to cardiogenic shock, the left ventricle is compliant, and the mitral valve is frequently 
incompetent as a result of chronic annular dilation and mitral valve leaflet tethering. Mitral 
regurgitation in this setting decompresses the left ventricle to some extent but may result in 
elevation of left atrial pressure and pulmonary edema [21, 37]. In contrast, acute myocarditis 
or myocardial infarction is associated with a noncompliant left ventricle and competent mitral 
valve. LV distension in this setting will result in a significant rise in intraventricular pressure 
and wall tension, which could be detrimental to the damaged myocardium, and reduced coro-
nary blood flow, causing subendocardial myocardial ischemia [38]. Aortic regurgitation should 
always be kept into account in ECMO patients due to its potentially detrimental effects [39].
Commonly, myocardial recovery on VA-ECMO support is suggested by an increase in pulse 
pressure and by improved contractility on echocardiography, but the appearance of pulsatility 
on the arterial waveform may also reflect a worsening volume overload. Tracking PCWP or 
repeat echocardiographic assessment may help to ascertain to manage the patient at the best.
The ultimate test of myocardial recovery, however, is accomplished by assessing hemo-
dynamic stability on minimal or no support. Under adequate heparinization, the “dose” 
of VA-ECMO can be decreased to achieve ~1 L/min of flow or the cannulas can be briefly 
clamped to ascertain the ability of the native ventricle to handle the full cardiac output. 
When the myocardium has recovered, during the weaning phases or temporary withdrawal, 
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acceptable contractility on echocardiography and stable hemodynamics (MAP, CVP and 
heart rate) has to be checked. We provide a schematic view of the Flow-chart for ECMO 
management form step 1 to step 4 and complete weaning (Figure 2). Hypotension, a rising 
Figure 3. Flow-chart describing the suggested therapeutical strategy according to patient’s clinical conditions and needs.
Figure 2. Flow-chart for ECMO management.
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CVP, atrial fibrillation, and a poorly contractile myocardium on echocardiography suggest 
weak recovery and a high risk of need of support [40, 41]. Recently, the group of Esposito 
and Kapur [42] has suggested a facilitating effect in withdrawal when the patients have 
an Impella in place to sustain left ventricular function. This knowledge, merged with the 
knowledge of the need of a short period of ECMO support and to the capability of Impella to 
interrupt the vicious cycle leading the patient to biventricular failure, may suggest the adop-
tion of Impella when cardiac power output falls under 0.6 and IABP is judged not enough 
to maintain adequate end-organ perfusion [43], in this case ECMO need has to be evaluated. 
In Figure 3, it has been represented a scheme of the associations between patients’ clinical 
conditions and the suggested therapeutical strategy to face patients’ hemodynamic needs.
4. IABP during ECMO
Intra-aortic balloon pump (IABP) has long been clinically applied to augment pulsatility, 
decrease afterload, and improve blood flow in native coronary arteries and bypass grafts [44, 45].
The inflations and deflations of the 30–50 ml balloon delivered by the IABP device are syn-
chronized with cardiac cycle: the deflation just before systolic ejection aims to decrease after-
load and improve LV ejection, while the inflation during diastole warrants increased diastolic 
perfusion aiming at improve coronary, cerebral, and visceral blood flow.
Despite the controversial data from the Intra-Aortic Balloon Pump in cardiogenic SHOCK 
(IABP-SHOCK) II trial [1], IABP currently remains one of the most commonly used mechani-
cal circulatory support devices in the treatment of acute heart failure. When administered 
promptly, it can play a critical role in the rescue of patients with acute myocardial damage, 
reversing the ongoing vicious cycle leading to death. It has been shown in animal models that 
IABP may improve several parameters of LV performance during VA-ECMO support [46]. 
Currently, several centers use IABP during VA-ECMO therapy to reduce LV afterload and 
warrant pulsatility in the end-organ capillary bed [47]. In a group of 219 patients treated with 
VA-ECMO after cardiac surgery, Doll et al. [18] found that the use of IABP during ECMO 
support was associated with a significantly higher survival rate. Ma et al. [48] reported 54 
adult patients with acute heart failure who received combined ECMO and IABP support, all 
of whom showed improvements in terms of overall circulation. Thirty-four of the patients 
were successfully weaned from mechanical circulatory support, and 21 (39%) survived to 
hospital discharge. Petroni et al. [49] showed that adding an IABP to peripheral VA-ECMO 
was associated with improved LV function, and discontinuation of intra-aortic balloon pump-
ing was associated with higher pulmonary artery wedge pressure, increased LV end-, and 
end-diastolic diameters, while decreasing pulse pressure (15 ± 13 versus 29 ± 22 mmHg; 
P = 0.02) [49]. Park et al. [50] did not find any mortality or morbidity benefit with IABP in 
the group of 96 VA-ECMO-treated patients with cardiogenic shock due to acute myocardial 
infarction. Recent data coming out from the Shock trial suggest that cardiac power output 
(CPO = cardiac output × MAP × 0.022) may be the best predictor of the effectiveness of IABP 
during impending cardiogenic shock [51]. Impella or VA-ECMO is needed when CPO is very 
low or upgrading of the MCS is necessary. Eventually the upgrade to ECMO or ECPELLA 
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(VA-ECMO + IMPELLA) may portend both optimal perfusion and ventricular unloading aim-
ing to myocardial recovery. Etiologic definition and eventual correction of the cause should 
be mandatory to increase the chance of recovery.
A marked increase in systemic blood pressure caused by VA-ECMO and retrograde aortic 
ECMO flow may increase cardiac afterload, together with severe systolic dysfunction, result-
ing in LV overload with a subsequent increase in left atrial pressure, severe pulmonary edema, 
myocardial ischemia, elevated pulmonary pressures, blood stasis, and potential thrombus 
formation, jeopardizing ventricular recovery.
Echocardiographic monitoring should be strictly recommended to detect a fluid overload 
early, and a Swan-Ganz catheter should be inserted to measure the pulmonary capillary 
wedge pressure to detect high left ventricular filling pressures as an indicator for left ven-
tricular distension. Ventilation with low tidal volumes and positive end-expiratory pressure 
(PEEP) has been suggested to keep the lung open. A higher PEEP is advisable in patients with 
ongoing pulmonary edema. Early extubation is feasible and desired when the patient has a 
low risk of pulmonary edema because optimal unloading.
To date, there are several possibilities to decrease the likelihood of left ventricular distension 
on ECMO, but the cohort of patients who benefit from left ventricular venting is unclear.
Decreasing afterload leads to a decrease in workload and O2 consumption. In case of an extremely poor left ventricular function, it is advisable to administer inotropes with a suf-
ficient mean arterial pressure of 50–60 mmHg. Physiologic lactate levels, normal pH levels, 
and regular central venous saturations as a guide and flow rates of 2.5–4 L/min are probably 
sufficient in most cases. Even if sometimes lower pump flow rates also reduce the perfusion-
related afterload [21].
Intra-aortic balloon pumping (IABP) concomitant to retrograde aortal perfusion is seen con-
troversial as the inflated balloon in the descending aorta might hinder proper perfusion. IABP 
counterpulsation is a device that inflates and deflates a 30–50 cm balloon in the descending 
aorta. The balloon inflations and deflations are synchronized with cardiac cycle, and, therefore, 
deflation just before systolic ejection may decrease afterload and improve LV ejection. Moreover, 
increased diastolic pressure on IABP could also improve coronary blood flow [52, 53].
Despite the general expectations that IABP is useful during VA-ECMO for a supposed “perfu-
sion benefit” which indeed is overcome by ECMO blood flow, our belief is that the rationale of 
the combined use of VA-ECMO and IABP is to provide a pressure unloading to the left ven-
tricle especially when a certain amount of residual SV is provided by the native circulation.
Although in a very unstable patient ECMO can stabilize end organs and restore their func-
tion, the lack of left ventricular unloading and reduced ventricular work threaten the myocar-
dium worsening the already impaired myocardial performance superimposing an extremely 
high afterload further compromising wall tension and myocardial oxygen demand. Multiple 
studies have shown that coronary perfusion worsens, especially if the patient is cannulated 
peripherally. Because relative cerebral or coronary hypoxia occurs in many situations due to 
a “watershed” effect, it is imperative to check blood saturations at multiple sites to determine 
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if perfusion is adequate everywhere to avoid to misdiagnose the “Harlequin syndrome” due 
to inadequate mixing of the two parallel circulations (ECMO and native heart) [23, 54, 55].
As a matter of fact, IABP should be already in place at the time of VA-ECMO implantation, 
as stated by ELSO Guidelines 2017 [www.elso.org]. For those patients who do not have one, 
it should be placed via the contralateral femoral artery, associating earlier the hemodynamic 
effects of IABP to those of VA-ECMO; from a mechanistic point of view IABP could neutralize 
some of the unwanted effects of VA-ECMO [56].
The role of IABP in patients suffering from cardiogenic shock should be highlighted as (I) 
it is rapidly deployable at any hospital and therefore reduces the duration of “uncontrolled 
shock”; (II) it allows, thereafter, safe transport to MCS units; (III) it does allow foe exploiting 
the same vascular access for Impella implant; and (IV) it has a major role in weaning from 
VA-ECMO and therefore reduces the burden of the complications related to ECLS.
Despite the controversial data from the intra-aortic balloon pump in cardiogenic SHOCK 
(IABP-SHOCK) II trial, which could not demonstrate a survival benefit for the IABP applica-
tion, IABP currently remains one of the most commonly used mechanical circulatory sup-
port devices in the treatment of acute heart failure. The bad news is that for none of the 
percutaneous devices, used in LV venting, a survival benefit has yet been documented in 
adequately sized randomized clinical trials (RCTs). A meta-analysis, by Cheng et al., includ-
ing a total of 100 patients in three small RCTs with the TandemHeart and the Impella PL2.5 
pump did not see a survival benefit in comparison to the IABP, despite better hemodynamic 
effects [57].
When administered in a timely manner, IABP can play a critical role in the rescue of patients 
with acute myocardial damage. It has been shown in animal models that insertion of IABP 
during VA-ECMO support may improve several parameters of LV performance and can 
reduce mean arterial pressure as well as oxygen saturation in the coronary sinus [24].
The combination of IABP and VA-ECMO can be found in the nationwide Japanese Diagnosis 
Procedure Combination national inpatient database; IABP combined with VA-ECMO was 
associated with reduced mortality and successful weaning from VA-ECMO. They also con-
cluded, of course, that randomized controlled studies are required to confirm the mortality-
reducing effect of the combination of IABP and VA-ECMO [57].
Despite the lack of clarity, in a systematic literature search, the use of concomitant IABP with 
ECMO is widespread. IABP was present in approximately 55% of all ECMO cases reviewed, 
stretching across all etiologies of cardiac failure beyond acute myocardial infarction (AMI).
The rationale for concomitant IABP use is primarily for LV venting [58]. The incremental ben-
efit of IABP support for afterload reduction and increasing organ perfusion in the presence of 
ECMO support is relatively minimal. Regarding improved diastolic pressures and coronary 
flow, despite the previously held belief of an estimated 11% survival benefit from pooled 
analyses of retrospective studies of IABP use in AMI, it is now known from the prospective 
and randomized IABP-SHOCK II study that the use of IABP in this cohort had no survival 
benefit [59].
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Early IABP, or, when CPO is very low and Impella offering the adequate flow, would sig-
nificantly impact the management of cardiogenic shock as it would avoid the administra-
tion of “toxic doses” of inotropes, allowing for smoother transition to VA-ECMO and routine 
unloading of the LV [44–60].
Even though, the combined use of IABP and VA-ECMO or Impella and VA-ECMO is well 
described to improve the hemodynamic facilitating and supporting conditions for recovery 
or ventricular assist device implantation [61, 62].
Recently, a simulation published on the ASAIO Journal [63] has supported the relevance of opti-
mal medical management, fluid removal while minimizing VA-ECMO flow, reducing blood 
pressure, and eventually adding inotropes to reduce PCWP and prevent pulmonary edema 
[64]. Recent clinical data support this notion for different clinical settings and do not advocate 
a routine combination of VA-ECMO and IABP. Clinical studies have shown a slight reduction 
in PCWP, LV dimensions, and pulmonary edema in-line with the computer simulation [65].
Patients showing PCWP above 25 mmHg or a virtually non-ejecting LV will require interven-
tional or surgical adjunct measures, which theoretically reduce PCWP by more than 5 mmHg. 
It has to be kept in mind that sometimes when you think of adding an unloading is too late 
for the patient, a proactive management reasoning on the patient characteristics and hemo-
dynamics is pivotal.
In a recent computer simulation, this combined approach showed only limited LV unloading, 
although pulsatility and increased stroke volume were noted. The CPO before VA-ECMO 
implantation and the native heart stroke volume after VA-ECMO implantation could be rel-
evant determinants of the effectiveness of IABP also during VA-ECMO perfusion (Figure 3), 
while a low PAPi may push toward biventricular support with Impella or TandemHeart.
5. Differences between atrial and ventricular unloading
When echocardiographic monitoring discloses surrogates of low contractility, LV distention 
or high filling pressure (PCWP) of the left ventricle, inotropic support should be considered or 
up titrated to increase contractility of the myocardium, and volume load should be assessed 
and eventually treated. Other conditions to be considered as drivers for unloading need have 
been represented in (Figure 4).
There are different drivers for atrial or ventricular unloading (Figure 5).
The kind of left side’s chamber decompression is strictly related to the mechanism of pulmo-
nary congestion and left ventricular distension. The variables that need to be kept in mind are:
• Adequacy of venous drainage: if the venous drainage may be considered poor, placement 
of pulmonary artery or left atrial drainage (comprised septostomy) may be sufficient.
• Mitral regurgitation: atrial drainage may be sufficient to unload the ventricle if a significant 
mitral regurgitation impedes the distension of the left ventricle.
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• Reversibility of left ventricle damage: ventricular unloading is pivotal to increase the 
chance of recovery.
• Aortic regurgitation: addressing aortic valve may be needed to avoid blood recirculation 
and stagnation.
Figure 6 shows the decisional process of management of conditions that may require unload-
ing if not properly treated, the only condition where unloading seems to be mandatory is 
smoking effect or slow flow through the MV. Figure 7 shows the possible surgical invasive, 
minimally invasive and percutaneous approaches aiming at ventricle unloading. When atrial 
unloading may be sufficient, a percutaneous left atrial septostomy may be accomplished, 
which allows blood from the LA to drain down its pressure gradient into the right atrium 
(RA) to then be drained via the venous cannula. This procedure is quite common in many 
hemodynamic lab especially used to treat pediatric patients. A cannula may also be placed 
into the LA through a transseptal puncture to facilitate drainage [66]. In addition, the left 
atrium or left ventricle can be directly cannulated allowing blood to be vented into the venous 
arm of the ECMO circuit. The transition to a BiVAD (TandemHeart or Centrimag or Rotaflow) 
could be considered if the oxygenator is no longer needed [67]. Finally, the use of a left ven-
tricular assist device such as the Impella (Abiomed, Danvers, MA) or BiPella (left and right 
Impella RP) [68] to provide left ventricular decompression as well as forward flow has been 
described and is gaining success due to its ease also bedside.
Figure 4. Factors driving unloading need in crash and burn patients. It has to be considered the possibility of unloading 
LV if signs of fluid overload (high pulsatility and LV distension at Echo and hemodynamic data) are not effectively 
treated with diuretics. Unloading is needed when there is low or absent LVEF, absent pulsatility without vasodilatation, 
smoking effect or slow flow through the MV.
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Figure 6. Management of conditions that may require unloading if not properly treated.
Figure 5. Atrial or ventricular unloading, decision making graph. In the graph, the pathological conditions in the blue 
dots are drivers of ventricular unloading while that ones in the red dots are drivers for atrial decompression. In green 
the first step therapy according to etiology.
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Left-to-right shunt can achieve effective decompression of the left ventricle in the setting of 
VA-ECMO at the presence of atrial communication (atrial septal defect or patent foramen 
ovale); atrial shunt can be, however, created also artificially with a percutaneous blade or 
balloon septostomy [69]. The procedure may be fruitful to induce pulmonary decongestion 
reducing atrial pressure and pulmonary edema but led to a suboptimal LV decompression.
An alternative way to perform atrial unloading, under guidance by bedside transoesophageal 
echocardiography, is by transseptal puncture and placement of a drain (8 Fr to 15 Fr). The 
percutaneous atrial transseptal cannula can then be placed and connected to the inflow part 
of the ECMO circuit, thus, decompressing the pulmonary circulation [70].
The left ventricle can be vented directly by placing a transaortic vent through the axillary 
artery or by echocardiography-guided insertion of a pigtail catheter into the left ventricle 
through the aortic valve and connected to the inflow part of the ECMO circuit [71]. Fumagalli 
et al. [72] achieved the decompression with a catheter placed percutaneously through the 
aortic valve into the left ventricle. The blood drained from the left ventricle was pumped into 
the femoral artery through the VA-ECMO circuit. The normalization of left heart filling pres-
sures led to the resolution of pulmonary edema, and the patient underwent successful heart 
transplantation. Barbone et al. [73] claimed LV unloading with a 7 Fr pigtail catheter inserted 
into the left ventricle via the femoral artery contralateral to the arterial outflow cannula. Using 
this approach in three different patients, the authors described resolution of LV distension 
and prevention of lung congestion without major complications. However, a so long and tight 
Figure 7. Surgical invasive, minimally invasive and percutaneous approaches to ventricle unloading.
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Figure 8. Techniques to unload the heart during ECMO. (1) Pathophysiology of LV distension during ECMO and (2) 
Impella on top of ECMO (ECPELLA): pathophysiology.
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line may be argued ineffective to warrant a large amount of drainage as it is generally needed. 
Indeed, a recent paper indicates an algorithm to select the right dimension of the pig aiming 
to reach the right unloading flow [74].
An alternative approach to LV decompression is the percutaneous insertion of a venous can-
nula into the pulmonary artery and connection of this cannula to the inflow part of the ECMO 
circuit [75]. A small (15 Fr) venous cannula may be placed percutaneously to the pulmonary 
artery and connected to the ECMO circuit to decompress the left heart and to facilitate LV 
function. Surgical minimal invasive access to directly drain the pulmonary artery has been 
also suggested.
Impella (Abiomed Inc., USA) is a catheter-based transaortic axial flow pump that can be intro-
duced through a percutaneous femoral approach. The device is placed across the aortic valve 
and pumps up (2.5–5 L/min) of blood on the basis of the model (2.5, CP or 5 L) from the left 
ventricle to the ascending aorta. The 2.5 and the CP are placed in the groin percutaneously 
while the 5.0 is generally placed surgically in the right axillary artery to warrant to the patient 
the possibility to be extubated and ambulatory.
Koeckert et al. [75] reported the use of Impella LP 2.5 for left ventricle decompression in a 
70-year-old man with acutely decompensated heart failure who was placed on VA-ECMO for 
cardiogenic shock with severe pulmonary edema and respiratory failure. Both devices were 
successfully weaned on day 5 after myocardial recovery. Narain et al. [76] described a case 
involving 31-year-old man with fulminant myocarditis treated with the Impella device and 
Figure 9. Optimal Arterial Pressure on VA-ECMO (Copyright from ASAIO).
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VA-ECMO. On full mechanical circulatory support, the hemodynamic status improved, and 
both systems were explanted after 48 h. Many centers are now moving toward the adoption 
of Impella as bailout for weaning and to unload the ventricle during VA-ECMO even if many 
warnings have been expressed regarding the risks to add more complexity to the management 
of an already complex patient [77, 78]. Figure 8 shows the pathophisiology of Left Ventricle dis-
tention due to ECMO (Figure 8-1) and the effects of adding Impella during ECMO (Figure 8-2).
Figure 9 shows all the possible surgical and percutaneous solutions to unload the left cir-
culation, preventing pulmonary edema and, possibly, facilitating the myocardial recovery 
when the underlying disease is potentially reversible. According to what said before, to reach 
patient survival, from end-organ function to myocardial recovery, we should balance arterial 
pressure, flow rate and unloading passing through IABP if necessary. The delicate balance of 
this therapeutical strategy is described in Figure 10.
6. Arterial pressure management during ECMO
While maintenance of flows is crucial to the care of the patient on VA-ECMO, attention must 
also be paid to the mean arterial pressure, as the end organs require both a cardiac output and 
a perfusion pressure for optimal function and a low venous pressure. A goal MAP >65 mmHg 
may be used as a starting point but can be adjusted either lower or higher given individual 
circumstances keeping in mind that the differential pressure between MAP and LAP is the 
driving force of organ perfusion and function. On the other side, MAP should never exceed 
90 mmHg to limit afterload and to promote forward flow, especially when peripheral 
Figure 10. Patient survival from end-organ function to myocardial recovery.
Advances in Extra-corporeal Perfusion Therapies200
cannulation limits the adequacy of drainage and leaves a remarkable amount of blood stag-
nating in the lung bed. A recent paper on the ASAIO Journal showed an inverse relation-
ship between mortality and MAP in VA-ECMO but not in VV-ECMO (Figure 10) [79]. In the 
hypotensive patient, MAP may be increased by manipulating either CO or SVR. The total 
cardiac output of the body is composed of native cardiac output and VA-ECMO flows. Thus, 
hypotension may potentially be corrected by increasing VA-ECMO flows and its contribution 
to total CO. Assuming a centrifugal pump, this may be achieved by administering volume 
or by increasing the RPMs of the pump. If the problem is related to SVR, such as with septic 
shock, a vasoconstrictor may be needed to increase MAP, although this must be weighed 
against the effect of increased afterload and the increase in pressure work of the left ventricle.
Many different policies exist on the management of arterial pressure during VA-ECMO: one 
concern is about the equivalence of MAP in patients with or without pulsatility. Physiologic 
autoregulation is pivotal for end-organ perfusion and particularly for the brain and kidney. 
Many studies dealt with ideal MAP value in the ICU patient, the most identify a cutoff of 
65 mmHg, as a value usually sufficient also if the study [80] suggested a MAP of 75–85 as 
protective for acute kidney injury in patients with a previous history of hypertension. To our 
knowledge, however, there has been only few studies examining optimal MAP for patients on 
ECMO and evidences in support of every practice are still weak.
Clearly, the physiology of VA-ECMO patients is considerably different from other critically ill 
patients. Several studies identified to determine the optimal pressure on cardiopulmonary bypass 
(CPB) during cardiac surgery [81–83] and the majority supports a MAP higher than 70 mm Hg 
on CPB. VA-ECMO is quite different from CPB: CPB is usually initiated electively for patients on 
stable patients, while VA-ECMO intervenes on an unstable circulatory condition. Moreover, the 
circuit is not open as in the CPB, the heart is not arrested, and there is not a reservoir to avoid pul-
monary fluid overload. The heart is in a dynamic parallel circulation with ECMO aiming to reach 
an equilibrium to eject against incoming blood flow from the ECMO circuit. The amount of work-
load may often be incompatible with the failing heart performance of most VA-ECMO patients. 
VA-ECMO could induce increased afterload and further worsen myocardial dysfunction. If a lower 
MAP could have the rationale to permit the heart to eject against a lower resistance decreasing the 
myocardial oxygen demand, the clinical impact of hypotension on the patient in cardiogenic shock 
has to be carefully judged. Furthermore, it may not be suitable to compare the MAP of patients 
with and without pulsatility because patients without pulsatility may require a higher MAP for 
end-organ perfusion. It may not be suitable to compare the MAP of patients with and without 
pulsatility because patients without pulsatility may require a higher MAP for end-organ perfusion.
Pulsatility is a dynamic property due to the interaction between the two concurrent parallel circu-
lations; indeed a loss of pulsatility may signal worsening myocardial function, while the appear-
ance of pulsatility or an improvement in pulse pressure may signal recovery. However, the loss of 
pulsatility may also suggest that VA-ECMO flows are too high, so reducing the amount of blood 
managed from the impaired native circulation. The higher the ECMO flows, the more blood that 
drains into the circuit causing a more significant decrease in LV preload, stroke volume, and 
pulse pressure. Total bypass, where the ECMO circuit takes over 100% of the cardiac output, 
creates a flat, non-pulsatile arterial tracing and signifies the lack of ejection of blood from the left 
Flow Optimization, Management, and Prevention of LV Distention during VA-ECMO
http://dx.doi.org/10.5772/intechopen.80265
201
ventricle. A recent study from Sakir Akin and the Erasmus group has shown how the peripheral 
recovery of pulsatility is a predictor of recovery that should push to weaning of ECMO [84].
Reduced pulsatility may also reflect a decrease in intravascular volume or a mechanical cause 
of decreased venous return (i.e., atrial tamponade) that may cause a decrease in LV preload 
leading decreased stroke volume and pulse pressure.
VA-ECMO reduces the volume work of the right ventricle through the decreased RV pre-
load, while pulmonary edema may cause hypoxic pulmonary vasoconstriction worsening 
pulmonary hypertension and increasing RV pressure work. If this setting, the right ventricle 
may be unable to pump to the left side of the heart, flattening arterial pressure waveform and 
decreasing the stroke volume. Nitric oxide with inodilators such as milrinone and dobuta-
mine (which will also provide inotropic assistance) are needed. If systemic pressures allow, 
nitroglycerin or nitroprusside may also be utilized.
7. Conclusions
Today, the first indication of treatment is weaning from ECMO and myocardial recovery. 
This target is more frequently achieved in myocarditis or potentially reversible diseases and 
stresses the importance of etiological diagnosis at the moment of implantation to define the 
strategy of implantation. In Figure 11 there is a flow chart that clarifies how VA-ECMO should 
be managed, according to the etiology, to reach the weaning from ECMO goal and myocardial 
recovery, analysing the phases of the hemodynamic support and detecting unloading need 
at the right time.
Figure 11. Flow chart on VA-ECMO management according to etiology.
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VA-ECMO has to be deemed as temporary short-term support, and the risks related to the 
permanence of an oxygenator must focus on a rapid transition to further MCS systems. The 
assessment of left atrial pressure (direct or indirect) should be a mandatory tool in patients 
with VA-ECMO to increase the chance of recovery or transition to next support or treatment. 
When left atrial pressure is deemed increased in surgical unloading, or percutaneous unload-
ing has to be considered preferring whenever possible ventricular unloading especially when 
mitral regurgitation is absent.
Randomized trials and registries will have to answer some of the open questions the clinician 
has to solve daily, dealing with the patient on VA-ECMO:
• Which goal directs the “dose” of VA-ECMO?
• Does one VA-ECMO configuration fit all?
• When unload before and when after VA-ECMO institution?
• Which clinical and hemodynamic profiles favor upfront VA-ECMO with LV venting?
• To vent or not to vent?
• When is vent mandatory?
• How vent without harm the patient?
• Should we transition to durable LVAD or BiVAD as soon as the end organs recovers?
• What are the granular aspects of management that should be included in trial design for 
VA-ECMO and LV venting?
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